Merck’s Keytruda trial a boost for kidney cancer patients
The immunotherapy used with Pfizer’s Inlyta halves the risk of dying from condition
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Kidney Cancer | Pharmaceuticals | Urology & Nephrology